The abstract is read at the publisher; the summary is JClub's.
In Noonan syndrome models, cardiac fibroblast IL-8–CXCR1 signaling is linked to fibrosis-related signatures, tissue stiffness, and cardiomyocyte hypertrophy, and reparixin reverses these effects.
- Why it matters: RAS-MAPK variants in Noonan syndrome cause severe, early-onset hypertrophic cardiomyopathy, but the paracrine mechanism driving fibrosis and hypertrophy is not well defined.
- What they did: Using two- and three-dimensional human induced pluripotent stem cell models of LZTR1 deficiency and patient-derived induced pluripotent stem cells with pathogenic RAS-MAPK gene variants, the study tested IL-8–CXCR1 signaling and inhibited it with reparixin.
- The result: IL-8–CXCR1 inhibition reversed pathological changes in cardiac fibroblasts and cardiomyocytes, supporting IL-8–CXCR1 as a heart-autonomous therapeutic target for NS-associated HCM.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.